Condition: Solid Cancer · GPC3 Positive Hepatocellular Carcinoma · Sponsor: Beijing GoBroad Hospital
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
This description comes directly from the study's public registry record.
Changsong Qi · +8601050847838 · xiwangpku@126.com
Always discuss trial participation with your own doctor first.
| Beijing Gobroad Hospital | Beijing, Beijing Municipality, China | Recruiting |
| GoBroad Healthcare Group | Beijing, Beijing Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07242417